ESTRO 2024 - Abstract Book

S2185

Clinical - Upper GI

ESTRO 2024

beam therapy (PBT) has the potential to offer better tumor control while preserving adequate liver function. Our study aims to compare the clinical outcomes between the PBT and TACE.

Material/Methods:

We conducted a propensity score-matched cohort study based on our multi-institution medical organization research database. HCC patients over 18 years old, diagnosed with BCLC stage B, and initially treated with PBT or TACE were included. The survival outcome of PBT versus TACE was compared. Stratified analysis was also performed to assess the heterogeneous effects between the two arms.

Results:

Four thousand one hundred and nine BCLC stage B HCC patients were identified from 2007 to 2021. Of these, 1112 patients met the inclusion criteria (PBT: 55 patients; TACE: 1057 patients). Two hundred seventy-five patients (PBT: 55; TACE: 220) were analyzed in the propensity-matched series. The matched groups were balanced for baseline tumor risk factors. PBT demonstrates a significant survival benefit over the TACE. The median overall survival (OS) was 2.25 years in the PBT group and 1.67 years in the TACE group (hazard ratio (HR): 1.68; 95% CI=1.07 – 2.64; p=0.025). The 1-year and 2-year OS for PBT versus TACE was 75.6% vs. 65.3% and 59.9% vs. 40.8%, respectively.